title: Additional evidence for the anti-inflammatory and anti-allergic properties of the sesquiterpene polygodial.
abstract: This study evaluates further the anti-inflammatory and anti-allergic properties of polygodial, a sesquiterpene extracted from the barks plant Drymis winteri (Winteraceae). Polygodial (12.8-128.1 micromol/kg, i.p.) 30 min prior, inhibited significantly the mouse paw oedema induced by prostaglandin E2, bradykinin (BK) substance P (SP), dextran, platelet activating factor (PAF) or carrageenan. Polygodial also inhibited arachidonic acid-, capsaicin- and croton oil-induced ear oedema in mice. Polygodial (42.7 micromol/kg, i.p.), significantly inhibited both exudation and cell influx when assessed in the pleurisy induced by SP and histamine, and to a less extent the inflammatory response caused by carrageenan, PAF, BK and des-Arg9-BK. Finally, polygodial (4.2-42.7 micromol/kg, i.p.) produced dose-related inhibition of paw oedema induced by ovalbumin, protecting in a time-dependent manner the anaphylactic shock induced by endovenous administration of ovalbumin in animals which had been actively sensitised by this antigen. These and our previous results indicate that the major component present in the bark of the plant D. winteri, the sesquiterpene polygodial exerts an interesting anti-inflammatory and anti-allergic properties when assessed in rats and mice.
authors.affiliation: Department of Pharmacology, Centre of Biological Sciences Universidade Federal de Santa Catarina, Florianópolis, SC, Brazil.
authors.forename: F M
authors.initials: FM
authors.lastname: da Cunha
authors.forename: T S
authors.initials: TS
authors.lastname: Fröde
authors.forename: G L
authors.initials: GL
authors.lastname: Mendes
authors.forename: A
authors.initials: A
authors.lastname: Malheiros
authors.forename: V
authors.initials: V
authors.lastname: Cechinel Filho
authors.forename: R A
authors.initials: RA
authors.lastname: Yunes
authors.forename: J B
authors.initials: JB
authors.lastname: Calixto
mesh_terms: D000707:Anaphylaxis / Q000209:etiology / Q000517:prevention & control; D000818:Animals; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D002351:Carrageenan / Q000009:adverse effects; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004487:Edema / Q000139:chemically induced / Q000188:drug therapy; D005260:Female; D006614:Hindlimb / Q000187:drug effects / Q000473:pathology; D018836:Inflammation Mediators / Q000009:adverse effects / Q000037:antagonists & inhibitors; D008297:Male; D051379:Mice; D010047:Ovalbumin / Q000009:adverse effects / Q000276:immunology; D010998:Pleurisy / Q000139:chemically induced / Q000188:drug therapy; D051381:Rats; D017208:Rats, Wistar; D012717:Sesquiterpenes / Q000627:therapeutic use*
chemical_list: D018926:Anti-Allergic Agents; D000893:Anti-Inflammatory Agents; D018836:Inflammation Mediators; D012717:Sesquiterpenes; C034380:polygodial; D002351:Carrageenan; D010047:Ovalbumin